Press releases
STORM Therapeutics (“STORM”), the drug discovery company tackling disease through modulating RNA modifying enzymes, today announced that it has raised an additional £14 million bringing the total Series A financing to £30 million.
Read more
STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, and The University of Cambridge announced today that they have been granted a Knowledge Transfer Partnership (KTP). The Grant, of up to £240,000, is to develop an analysis platform using the data warehouse software InterMine to help STORM advance its cancer research.
Read more
STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announced that it will be giving a company presentation at Bio€quity Europe 2018, Ghent, Belgium, 14 - 16 May 2018.
Read more
STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announced that it has won the Life Science Innovation Award at the Business Weekly Awards ceremony.
Read more
STORM Therapeutics today announced the appointment of Nobel Prize Winner Professor Thomas Cech as a Scientific Advisor. This appointment follows STORM Therapeutics’ successful Series A Financing Extension announced in January 2018.
Read more